Developing Countries Vaccine Manufacturers Network

Speakers’ Book

22nd Annual General Meeting 2021
October 19th – 21st, 2021

The 22nd Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers’ Network (DCVMN) co-hosted virtually by DCVMN along with member company Biovac from Cape Town, South Africa.

2021 DCVMN-AGM’s theme is “Vaccines: New Challenges, New Paradigms, New Opportunities!” with a high focus on vaccine equity and self-sufficiency to vaccine manufacturing in Africa.
DAY 1, October 19th 2021
11:00am - 12:40pm CET
Inaugural Session

Chair: 
Dr. Morena Makhoana  
CEO, Biovac

Dr. Morena is the CEO of Biovac. His aim is to build vaccine manufacturing capacity in South Africa through Biovac, due to Africa’s limited capability in human vaccine manufacture. During his tenure Biovac has deepened its product development capability and also secure technology transfers with global multinationals. Dr. Morena is a medical graduate from the University of Cape Town, South Africa.

Chair: 
Mr. Sai D. Prasad  
Board Chair, DCVMN & Executive Director, Bharat

Sai Prasad is the Executive Director at Bharat Biotech. He is responsible for crucial decisions in the company with respect to operations, business development and International Collaborations. He has expertise in areas not restricted to product development, contract negotiations, technology licensing, mergers & acquisitions, fund raising, overall operations, etc.

H.E. Dr. B. M. Nzimande  
MP, Minister of Higher Education, Science and Innovation

Dr. Nzimande was appointed as Minister of Higher Education, Science and Technology on May 2019. He was Minister of Transport between 2018 and 2019. In addition, he was the Minister of Higher Education and Training in the Republic of South Africa from May to October 2019. His background includes some publications on sociology, school education, and democracy as well.
Dr. Tedros A. Ghebreyesus  
*Director General, WHO*

A globally recognized health scholar, researcher, and diplomat, Dr. Tedros was elected WHO Director General in 2017. Immediately after taking office, Dr. Tedros outlined five key priorities for the Organization: Universal Health Coverage; Health Emergencies; Women’s, Children’s and Adolescents’ Health; Health impacts of climate and environmental change; and transformed WHO.

---

Dr. Bruce Aylward  
*Senior Advisor to Director General, WHO*

Dr. Aylward is a Canadian physician and epidemiologist who leads the multi-agency Access to COVID-19 Tools Accelerator (ACT-A) Hub, an international collaboration to fast-track the development and equitable global distribution of new COVID-19 diagnostics, therapeutics and vaccines. Since the 1990s, Dr Aylward has worked for WHO in a variety of increasing leadership positions in the areas of emergencies, disease eradication and vaccines.

---

Dr. Seth Berkley  
*CEO, GAVI*

Dr. Seth Berkley is an epidemiologist and the CEO of Gavi, the Vaccine Alliance, the global health organization which improves access to vaccines in developing countries. Currently, he is leading Gavi’s efforts to build sustainability into country immunization programs. Prior to Gavi, he spearheaded the development of vaccines for HIV as founder and CEO of the International AIDS Vaccine Initiative.
<table>
<thead>
<tr>
<th>Dr. Richard Hatchett</th>
<th>CEO, CEPI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard J. Hatchett, MD, is Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI), a partnership of public, private, philanthropic and civil organizations that supports the development of vaccines against high priority public health threats and technology platforms to allow the rapid development of vaccines against emerging infectious diseases such as COVID-19.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dr. David C. Kaslow</th>
<th>CSO, PATH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Kaslow is Chief Scientific Officer at PATH where he heads PATH Essential Medicines, which includes Drug Development and the PATH Center for Vaccine Innovation and Access (CVIA). Before joining PATH in 2012, he served as a Vice-President, Vaccines and Infectious Diseases Franchise at Merck Research Laboratories, MSD.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dr. Derrick Sim</th>
<th>Director of Vaccine Supply &amp; Demand, GAVI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Derick Sim is currently the Director of Vaccines Demand and Supply at Gavi, the Vaccine Alliance and serves as the Vice President and Global Vaccines Commercialisation Leader - Rotarix and Synflorix.</td>
<td></td>
</tr>
</tbody>
</table>
Dr. Soumya Swaminathan

Dr. Soumya Swaminathan was appointed WHO’s first Chief Scientist in March 2019. She is a paediatrician and a globally recognized researcher on tuberculosis and HIV. Dr Swaminathan was Secretary to the Government of India for Health Research and Director General of the Indian Council of Medical Research from 2015 to 2017. She received her academic training in India, the United Kingdom, and the United States of America, and has published more than 450 peer-reviewed publications and book chapters. The Science division’s role is to ensure that WHO stays ahead of the curve and leverages advances in science and technology for public health and clinical care, as well as ensuring that the norms, standards and guidelines produced by WHO are scientifically excellent, relevant and timely.

Dr. Solomon Zewdu

Dr. Zewdu is a medical doctor and Deputy director in the Africa Regional Office of the Bill and Melinda Gates foundation, in South Africa, where he oversees the foundation’s health and health related continental investments. He is the Gates foundation’s Covid-19 pandemic response coordinator for Africa. He joined the foundation after having managed one of the largest US President's Emergency Plan for AIDS Relief program in Ethiopia.

Dr. Rogério Paulo Pinto de Sá Gaspar

Rogério Gaspar (Pharmacist, PhD), Director of the Department of Regulation and Prequalification at WHO. An academic for the last 36 years, with extensive international regulatory experience. Previously Vice-President of INFARMED, member of the MB of EMA (2000-2002), Vice-Rector of the University of Lisbon (2013-2017), member of the Executive Committee and Vice-President of the European Federation of Pharmaceutical Sciences (EUFEPS, 2009-2013; 2016-2020).
DAY 1, October 19th 2021
12:40pm - 01:30pm CET
Session 2 – Innovations in vaccine space

Moderator: 
Mr. Rajinder Suri
CEO, DCVMN
Rajinder Suri is CEO-DCVMN. Currently, he is part of ACT-A implementing partners, COVAX Manufacturing Task Force Leadership Team and advisory expert groups on Market design & intelligence committee of PAVM. He previously worked as a Chief Executive-Biologicals, Panacea Biotec Ltd. Has been Member-Gavi-Policy & Planning Committee (PPC) as well as Vice-President, and DCVMN Executive Committee, bringing 40 years of experience.

Dr. John Nkengasong
Director, Africa CDC
Dr. Nkengasong is the first Director of the Africa Centres for Disease Control and Prevention (Africa CDC). He is a leading virologist with nearly 30 years of work experience in public health. In addition, he serves as one of the WHO Director-General’s Special Envoys on COVID-19 Preparedness and Response. He has brought meaningful contributions to international journals and book chapters.

Prof. William K. Ampofo
Chair, AVMI
William K. Ampofo is Associate Professor Virology, University of Ghana, has conducted various global assignments on viral pathogens. Currently, he is member of the Influenza Vaccines Roadmap Taskforce, ECOWAS Vaccines Task Force and member and the Global Pandemic Radar. He is Secretary, Presidential Committee for Vaccine Manufacturing in Ghana and chair of the African Vaccine Manufacturing Initiative.
Dr. Carissa F. Etienne  
**Director, PAHO**

Dr. Etienne, a native of Dominica, was elected for a second five-year term as the Director of the Pan American Health Organization, Regional Office of the World Health Organization in 2017. Dr. Etienne served as Assistant Director-General for Health Systems and Services at the World Health Organization in Geneva, Switzerland from 2008 to 2012.

Ms. Aurélie Nguyen  
**Managing Director, COVAX**

Ms. Aurélia, a public health leader of Vietnamese origin, is the Managing Director of the Office of the COVAX Facility, responsible for leading the procurement and delivery of Covid-19 vaccines to over 190 economies. She also served as Gavi’s Managing Director for Vaccines & Sustainability, designing Gavi’s vaccine programmes.

Mr. Thomas B. Cueni  
**Director General, IFPMA**

Mr. Cueni is Director General of IFPMA, the global association of pharmaceutical research companies. Thomas Cueni represents the Access to COVID-19 Tools (ACT) Accelerator. He is Chair of the Business at OECD Health Committee and serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. He created the AMR Action Fund and he is Chair of the Board of the cross-sectoral AMR Industry Alliance.
Dr. Mariângela B. G. Simão  
*Assistant Director General, Access to Medicines and Health Products, WHO*

Dr. Mariângela Simão is the Assistant Director-General, Access to Medicines and Health Products; she has over 30 years of experience in the Brazilian health system. In this capacity, she actively enhanced a more equal access and decentralized management of health services in the country.

Dr. Michelle McMurry–Heath  
*President and CEO, BIO*

Dr. McMurry-Heath is the President and CEO of the Biotechnology Innovation Organization (BIO). A medical doctor and molecular immunologist by training, she is the third chief executive to steward the world’s largest biotechnology advocacy group. She advocates for the fair distribution of science and innovation, calling “the distribution of scientific progress the social justice issue of our age”.

Dr. Jerome H. Kim  
*Director General, IVI*

Jerome H. Kim, M.D., is an international expert on the development and evaluation of vaccines and is the Director General of the International Vaccine Institute (IVI), whose mission is to discover, develop and deliver safe, effective, and affordable vaccines for Global Health.
DAY 1, October 19th 2021
01:40pm - 02:40pm CET
Session 3 – CEO Forum: Vision 2030

Moderator:
Mr. Joshua Chu

Executive Vice President of Vaccines and Non–Communicable Diseases, CHAI

Mr. Chu is Executive Vice President of Vaccines and Non-Communicable Diseases at the Clinton Health Access Initiative (CHAI). He is responsible for CHAI's work to accelerate the introduction of new vaccines, to strengthen implementation of national immunization strategies and to support market shaping strategies to improve the sustainability and affordability of essential vaccines. He also oversees CHAI's work in cancer, diabetes and cardiovascular diseases.

Mr. Jaeyong Ahn

CEO, SK Bio Sciences

Dr. Ahn is the first CEO at SK Bioscience and former senior vice president and head of SK Chemicals VAX business group in South Korea. He has UAB WHO Reference lab and invests in advancing pneumonia research worldwide and more affordable vaccines.

Ms. Mahima Datla

CEO, Bio E

Ms. Datla is the Managing Director of Biological E Limited, one of the leading vaccine manufacturers based in India. Over a career spanning 20 years, she has also held key positions in several public health organizations such as Gavi, DCVMN, GHIT and Hilleman Labs, representing her organization and the DCVMN.
Dr. Mauricio Z. Medeiros

**CEO, Bio Fiocruz**

Dr. Zuma is the elected Director at Bio-Manguinhos/Fiocruz, responsible for research, innovation, technological development and production of vaccines, diagnostic kits and biopharmaceuticals. He holds 39 years of public management and interests in strategies and technology transfer in Brazil.

---

Dr. Andrew Wong

**General Manager, Shanghai Wotai Biotechnology – Director of Business Development, China of Walvax Biotechnology**

Dr. Wong holds the position of General Manager at Shanghai Wotai Biotechnology, a Walvax subsidiary, and is the Director of Business Development at Walvax Biotechnology Ltd. He sustains more than 30 years of intercultural experience on molecular cancer drug, antibody therapeutics and human vaccine research. Andrew managed three collaboration projects to support the development of bivalent, nonavalent HPV vaccines and recombinant COVID-19 vaccines.

---

Dr. Alejandro Gil

**CEO, Sinergium Biotech**

Dr. Gil serves as President at Sinergium Biotech, a company that provides world class vaccines and biotechnological products. Before that, he acted as CEO of Biogenesis Bagó; a regional biotech company of animal health products and services. President at Caprove (Camara Argentina de la Industria de Productos Veterinarios). He holds a degree in Medical Veterinary.
Dr. Morena Makhoana  
**CEO, Biovac**

Dr. Morena is the CEO of Biovac. His aim is to build vaccine manufacturing capacity in South Africa through Biovac, due to Africa's limited capability in human vaccine manufacture. During his tenure Biovac has deepened its product development capability and also secure technology transfers with global multinationals. Dr. Morena is a medical graduate from the University of Cape Town, South Africa.
DAY 2, October 20th 2021
12:30pm - 01:30pm CET
Session 2 - Challenges and Opportunities in Vaccine Research and Availability

Moderator: Mr. Adriansjah Azhari  
Member, DCVMN Board

Mr. Azhari has vast experience in biotechnology, Quality Management including Good Manufacturing Practices. He is a pharmacist and holds a Master’s degree in Operations Management. He is currently a member of the Board of Executives of Bio Farma as Senior Executive Vice President (SEVP) overseeing Research and Development activities. He is also a member of DCVMN’s board and chair of DCVMN Covid-19 committee.

Ms. Lingjiang Yang  
Member, DCVMN Board

Mrs. Yang is responsible for all international cooperation development and management as well as international marketing. Her experience as the project coordinator of the WHO prequalification of live Japanese Encephalitis vaccine has given her insight into the global vaccine industry. She is also member of DCVMN's board and Chair of the Supply Chain Working Group.
Dr. Melanie Saville

Director Vaccine Development, CEPI

Dr. Saville leads a technical team that has oversight of the CEPI funded vaccines in development. Melanie is a physician specialized in virology with 20 years of experience in the development and licensure of vaccines for the developed and developing world. Over the years, she has contributed to the development and licensure of several vaccines internationally.

Ms. Etleva Kadilli

Director Supply Division, UNICEF

Ms. Kadilli is Director of UNICEF’s Supply Division in Copenhagen, Denmark, overseeing UNICEF’s global supply operations in development and emergency contexts, with an annual expenditure exceeding USD 4.4 billion. An Albanian national, Ms. Kadilli has worked for UNICEF for over 25 years in various supply and programme operations roles.

Prof. Pieter Neels

CEO and Scientific Advisor at Vaccine-Advice BV

Dr. Neels is the CEO and Scientific Advisor at Vaccine-Advice BV and an independent consultant for WHO and many vaccine developers. Dr. Neels is the chair of the vaccine committee at IABS, ex-CHMP member and ex-vice-chair of VWP and holds in-depth knowledge on vaccines and new medicinal products for diabetes, nephrology and many others.
Dr. Kate O’Brien

**Director Department of Immunization, Vaccines and Biologicals, WHO – Technical Lead, COVAX**

Dr. O’Brien is Director of the Immunization, Vaccines and Biologicals Department at WHO. In this role, she is responsible for leading WHO’s strategy and implementation to advance the vision of a world where everyone, everywhere, at every age, fully benefits from vaccines for good health and wellbeing. Dr. O’Brien also serves as WHO’s Technical Lead COVAX.

Ms. Carmen Rodriguez Hernandez

**Team Lead of Vaccines PQ at Regulation and Prequalification Department, WHO**

Pharmacist with specialization in Microbiology of Food, Cosmetics, medicines and Biologicals and Sanitary Pharmacology. Team lead of vaccines PQ and the Emergency use listing of vaccines as well as the risk benefit assessment of snake antivenoms. Thirty-one years of experience in the area of regulation of biologicals, including regulatory networks. Carmen Rodriguez Hernandez has written several publications in the area of regulation of vaccines.

Dr. Raman Rao

**CEO, Hilleman Laboratories**

Dr. Rao is the Chief Executive Officer at Hilleman Laboratories supporting the development of vaccines and Biologicals for Low and Middle-income countries. He has more than 20+ years of experience in Research and Development, Manufacturing and commercialization of vaccines and Biologics in global pharma and biotech companies.
DAY 2, October 20th 2021
01:30pm - 02:30pm CET
Session 3: Innovative Financing Mechanisms to ramp up Manufacturing in Africa and other LMICs

Moderator:
Mr. Patrick Tippoo
Vice President, DCVMN Board

Mr. Tippoo heads Science and Innovation at Biovac, in South Africa. He is a founding member and present Executive Director of the African Vaccine Manufacturing Initiative (AVMI) and currently serves as the Vice-President of DCVMN. Mr. Tippoo is also member of the DCVMN’s board.

Wrap-up:
Mr. Fernando Lobos
Treasurer, DCVMN Board

Mr. Lobos, Engineer and MBA, with 25-years’ experience in management, focused on new business development, engineering, start-up and operations of pharmaceutical companies. Previous experience includes positions as Operations Manager, Latin America Supply Chain Manager, Production Manager and Engineering Manager in top multinational companies starting in 1995. Mr. Lobos is a member of DCVMN’s board, and treasurer.

Dr. Akinwumi A. Adesina*
President, African Development Bank

Dr. Adesina is a Nigerian renowned development economist and agricultural development expert who served as the President of the African Development Bank Group. Having received important awards globally, he has brought significant agricultural investments in the benefit of more than 15 million farmers in his nation. It’s worth to mention has authored over 70 scholarly publications on his field of interest.
Ms. Gwen Mwaba

*Director of Trade Finance, Afreximbank*

Mr. Mwaba works as Director & Global Head of Trade Finance at the Afreximbank since 2015. In this role, she heads the Trade Finance business across Africa, where she has accumulated over 23 years of banking experience in sectors ranging from Oil & Gas, Telecoms, Hospitality, Mining and agri-business. Gwen holds a BSc. Applied Accounting and an MBA from Edinburgh Business School.

Mr. Sérgio Pimenta

*Regional Vice President for Africa, IFC*

Mr. Pimenta is IFC’s Regional Vice President for Africa. In this role, he is in charge of all advisory and investment operations in a region with a committed portfolio of $13.3 billion and more than 700 staff working to expand the private sector's role in addressing urgent development challenges in the financial, manufacturing, agribusiness and services, and infrastructure industries.

Prof. Robin Shattock

*Head of Mucosal Infection and Immunity, Imperial College London*

Dr. Shattock’s research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. He oversees a portfolio of research that is supported by 26 members of staff and has published over 200 peer-reviewed articles in this area.
Dr. Kelvin H. Lee

*Director, NIIMBL*

Dr. Lee is Gore Professor of Chemical and Biomolecular Engineering at the University of Delaware and is Director of NIIMBL: the National Institute for Innovation in Manufacturing Biopharmaceuticals. He received a BSE in Chemical Engineering from Princeton and PhD in Chemical Engineering from Caltech. He spent several years in the Biotechnology Institute at the ETH in Zurich, Switzerland and completed a postdoc in Caltech’s Biology Division.

Mr. Lin Xiangliang

*CEO & Founder, Esco Aster*

Dr. Lin started the Esco Group of Companies’ Healthcare division as a "Discovery to Delivery" platform establishing its global partners and factories in USA, UK, Taiwan, Singapore and Indonesia. He founded Esco Aster, a contract development and manufacturing organization, to translate bench work into life-saving diagnostics, medicines, therapies, vaccines, cosmeceuticals and cellular agriculture at affordable prices for a nation’s self-sufficiency."

Mr. Jon Pearman

*Supranational, Coordinator, Temptime*

Jon supports Temptime’s global health organization activities from Geneva. He has worked in Gavi Alliance for over 10 years as well as 17 years in Pharma: GSK, as well as Berna Biotech (now J&J). He holds a MSc in Molecular Biology and Biochemistry from Durham University, UK. Temptime is part of Zebra Technologies.
DAY 3, October 21stth 2021
11:00am - 12:10pm CET
Session 1: Priorities & Policies for LMICs – A multilateral View

Moderator: Mr. Tiago Rocca
Strategic Partnerships & Business Development Manager, Instituto Butantan
Mr. Rocca has been working at Butantan for over 14 years and has assumed responsibilities in vaccines and biopharmaceuticals production, technology transfer, validation and QA. He is a pharmacist and post-graduated in Health Law at Public Health School USP and in Pharma Business Management at ESPM. Currently is the Secretary of Emerging Biopharmaceuticals Manufacturers Network (EBPMN).

Prof. Gagandeep Kang
The Wellcome Trust Research Laboratory, Christian Medical College
Prof. Kang is widely known for her inter-disciplinary research studying the transmission, development and prevention of enteric infections and their sequelae in children in India. She is a member of the several advisory committees for the WHO, mainly related to research and use of vaccines and for several national and international institution. Prof. Kang has published over 400 papers.

Dr. Frank Cobelens
Chair, Department of Global Health, Amsterdam University
Dr. Cobelens is a physician and infectious disease epidemiologist who currently occupies the position of Professor of Global Health at the Amsterdam University Medical Centers, loc. AMC, UvA, & Amsterdam Inst. for Global health & Devel (AIGHD). He has over 25 years of experience in poverty-related infectious diseases and, more recently, global health, what is very noted in his 200 peer-reviewed papers, mainly on TB.
Prof. Tulio de Oliveira  
*Director of KRISP, University of KwaZulu-Natal*

Prof. Oliveira has a bachelor's in science at the Federal University of Rio Grande do Sul (UFRGS), Brazil and MSc/PhD at the Nelson R Mandela School of Medicine, UKZN, South Africa. Having been awarded two prestigious fellowships, he was also the Director of the Genomics Program at the Wellcome Trust Africa Centre for Health and Population.

Dr. Narendra K. Arora  
*Executive Director, INCLEN Trust International*

Prof. (Dr.) Arora MD, MMSc, is an Indian paediatrician who serves as the Executive Director of The INCLEN Trust International since 2005. He is well known as a public health expert and is extensively involved in policymaking, and program planning local and internationally, especially after publishing 165 original pieces of research.

Ms. Tania Cernuschi  
*Team Lead, Global Access, WHO*

Tania leads WHO IVB work on global access to vaccine. She has over seventeen-year experience in design and management of development programs enhancing access to health technologies in resource-constrained settings with Gavi, UNDESA, the Italian Government, UNICEF and NGOs. Tania is a development economist and public health specialist by training.
Dr. Fredrick Kristensen  
*Deputy CEO and Director of People, Planning and Policy, CEPI*

Dr. Kristensen has served as Deputy CEO at CEPI since January 2018. Previously, he was a senior advisor on innovation at WHO in Geneva, in the Family, Women’s and Children’s Health Cluster. In that capacity, he helped manage projects promoting access to critical life-saving commodities, supporting projects in numerous countries in Africa and South-East Asia in particular.

---

Dr. Brigitte K. Giersing  
*Team Lead Vaccine Platforms and Prioritisation (PDR), WHO*

Dr. Giersing is the Team Lead for Vaccine Prioritisation and Platforms in the Immunization, Vaccine & Biologicals (IVB) Department at WHO. She is also the secretariat for IVB’s Product Development Vaccine Advisory Committee (PDVAC) and focuses on vaccine product and delivery research for priority vaccines.

---

Dr. Jicui Dong  
*Unit Head, Local Production & Assistance Unit (LPA), Regulation and Prequalification Department (RPQ), Access to Medicines and Health Products Division (MHP), WHO*

Dr. Jicui DONG is the Unit Head of the WHO Local Production and Assistance Unit to support Member States in strengthening quality and sustainable local production of medicines, vaccines, diagnostics and other health products. Jicui received her MSc in Pharmacology in China, PhD in Biology in Switzerland, and MBA in the United Kingdom.
DAY 3, October 21st\textsuperscript{th} 2021
12:30pm – 01:35pm CET
Session 2: Facilitating Manufacturing Ramp-up – Suppliers View

Moderator:
Ms. Weidan Huang

Member, DCVMN Board

Ms. Huang joined Innovax in 2010. She has 11 years of experience in the vaccine industry and has participated in all stages of HPV vaccine development. Currently, Ms. Huang is Business Development Director, Xiamen INNOVAX Biotech and also the chief coordinator of the HPV vaccine product program and leads the WHO prequalification projects at Innovax.

Ms. Josephine Cheng

Senior Consultant, Core Modalities APAC, Merck KGaA

Josephine has over 14 years of pharmaceutical industry experience and held various regional roles in the technical and marketing field, led successful projects, and drove business development in the plasma and vaccine space. She looks closely into customer and market insights specifically in the Plasma and vaccine industry, develops regional strategic initiatives, and leads customer collaborations.

Mr. Tony Xu

Business Development Manager, Tofflon

Mr. Xu has over 10 years of experience in Biopharma and Pharma Equipment application. His expertise includes professional project management of all types of pharmaceutical machines/integrate system/New Facility Engineering and Biopharma Fermenter/Chromatography/Filtration/Solution preparation) Bulk line + Fill & Finish line. He is leading the business development team to achieve the goals according to Tofflon's overseas strategies.
Dr. Vibin B. Joseph

*Executive Director, BiOZEEN*

Vibin steers the strategic direction at Biozeen. He leads geographic expansion, business model evolution and process optimizations. He is an engineer with a major in mechanical and management degree from Imperial College London, and doctoral research from Warwick University. His research interests lie in systems design, design psychology and moderating influencers in the pharmaceutical industry.

Ms. Stephanie Krieg

*Process Engineer, Bioengineering AG*

Stephanie Krieg has worked over five years in the process engineering and innovation departments with Bioengineering AG, a leading Swiss design and fabrication partner for vaccine manufacturers around the world. Other than research-scale bioreactors to fully customized commercial production plants, Bioengineering also brings extensive know-how in revamping and adapting existing facilities to changing product requirements.

Dr. Andreas Castan

*Strategic Technology Partnerships Leader, Cytiva*

Dr. Andreas Castan has worked for more than 20 years in the biotech industry. Prior to joining Cytiva, Dr Castan was Director Upstream Development at Swedish Orphan Biovitrum. In this current role, Dr Castan provides leadership and support to Cytiva’s Bioprocess business. He is known for his profound expertise from scientific publications, book chapters, conference presentations, webinars, webcasts, interviews and articles.
Mr. Christian Lavarreda  
*Global Product Manager, Syntegon*

Mr. Lavarreda, based out of Germany, is currently global product manager for pure media, process, and bioprocess systems at Syntegon. Formally trained as a chemical engineer, he is responsible for leading the development, commercialization, and marketing of Syntegon’s pharmaceutical liquid processing portfolio. At Syntegon, he has included regional business development and marketing manager for liquid pharmaceutical primary packaging in North America.

---

**DAY 3, October 21st 2021**  
**01:35pm – 02:40pm CET**  
**Session 3: Panel Discussion – Sustainable Manufacturing in Africa**

Mr. Samir Desai  
*President & Head BU Biologics, Zydus Cadila*

Mr. Desai heads BU Biologics as President for Zydus Cadila covering Biologics, Vaccines, Diagnostics & specialty pharma with coverage of Hepatology, Oncology, Nephrology, Rheumatology, Gastroenterology, Orthopaedics & Ophthalmology. Samir is an Executive Board member at Centre for Global Hepatitis Elimination, Chair of the DCVMN Regulatory Working Group for Vaccines. Samir has published many papers in Peer Reviewed journals.

Mr. Rajinder Suri  
*CEO, DCVMN*

Rajinder Suri is CEO-DCVMN. Currently, he is part of ACT-A implementing partners, COVAX Manufacturing Task Force Leadership Team and advisory expert groups on Market design & intelligence committee of PAVM. He previously worked as a Chief Executive-Biologicals, Panacea Biotec Ltd. Has been Member-Gavi-Policy & Planning Committee (PPC) as well as Vice-President, and DCVMN Executive Committee, bringing 40 years of experience.
Dr. Matthew Downham  
*Sustainable Manufacturing Lead, CEPI*

Dr. Downham holds a PhD (Biochemical Engineering), a BSc (Industrial Biology) and a PGCE (Higher Education). He leads CEPI’s sustainable manufacturing team supporting CEPI vaccine development priority pathogen projects. Dr. Downham works with cross-functional teams/leadership, global stakeholders, vaccine manufacturing-supply chain partners establishing sustainable vaccine manufacture in alignment with CEPI strategy.

Dr. Martin Howell  
*Transfer of Technology for Health Products, WHO*

Dr. Friede leads the vaccine research unit at WHO in Geneva. Prior to joining WHO Dr. Friede held several senior roles in the pharmaceutical industry. He obtained his PhD in biochemistry from the university of Capetown in South Africa.

Dr. David Robinson  
*Deputy Director, CMC, Vaccines Development and Surveillance, The Bill and Melinda Gates Foundation*

David is Deputy Director, CMC Vaccines Development and Surveillance at the Bill & Melinda Gates Foundation. He has 30 years of experience in vaccine and biologics development. David received his BS from U.C. Berkeley, his Ph.D. from MIT and did postdoctoral research at the Swiss Federal Institute of Technology.
Dr. Morena Makhoana

**CEO, Biovac**

Dr. Morena is the CEO of Biovac. His aim is to build vaccine manufacturing capacity in South Africa through Biovac, due to Africa’s limited capability in human vaccine manufacture. During his tenure Biovac has deepened its product development capability and also secure technology transfers with global multinationals. Dr. Morena is a medical graduate from the University of Cape Town, South Africa.

Dr. Amadou Alpha Sall

**Director, Institute Pasteur de Dakar**

Dr. Sall, virologist, is the CEO of Institut Pasteur de Dakar in Senegal and the chairman of the Global Outbreak Alert and Response Network and director of the WHO collaborating center for Arboviruses and viral haemorrhagic fever. He is acknowledged by his expertise in epidemics response and control more specifically for arboviruses and viral haemorrhagic fevers (Ebola, Zika, Yellow fever …).

Dr. Ncaise Ndembali

**Chief Science Advisor, Africa CDC**

Dr. Ndembali, a virologist and public health expert, serves as the Chief Science Advisor for CDC since 2020, a Research Professor at Kanazawa University School of Medicine and Adjunct Associate Professor University of Maryland, USA. Dr. Ndembali brings a wealth of knowledge in molecular virology, Clinical trials, HIV therapy, HIV drug resistance and bioinformatic to his successful career.
Dr. Bartholomew Dicky Akanmori

Vaccine Regulation Officer in the Communicable and Non-communicable Diseases Cluster, WHO-AFRO

Prof. Akanmori, PhD in Immunology, is a Regional Adviser for Vaccine Research and Regulation in the WHO Regional Office based in Congo, since 2007. He is responsible for Vaccine Research, Regulation, and Safety, where he coordinates the Secretariat of the African Vaccine Regulatory Forum (AVAREF). He currently supports capacity building for regulatory and ethics oversight of vaccine clinical trials in Africa.

Dr. Janet Byaruhanga

Senior Programme Officer-Public Health, NEPAD

Dr. Byaruhanga is a qualified medical doctor and public health expert who joined the African Union Development Agency as a Senior Programme Officer-Health in 2017. With over 13 years of experience, she is in charge of policies on health and medical products, in alignment with the context of the African Union’s African Health Strategy and the Pharmaceutical Manufacturing Plan for Africa.